This project investigates a new strategy to improve immunotherapy for diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma. Despite advances such as CAR-T cells and bispecific antibodies, many patients still relapse or fail to achieve long-term remission. The project focuses on MCT1, a lactate transporter that supports tumor metabolism and may contribute to an immunosuppressive tumor microenvironment. Preliminary data suggest that high MCT1 expression is linked to more aggressive DLBCL, poorer survival, reduced cytotoxic T-cell signatures, and inferior CAR-T response. By pharmacologic MCT1 inhibition (AZD3965), the study aims to disrupt lymphoma metabolism, lower lactate-mediated immune suppression, and enhance the activity of CAR-T cells and bispecific antibodies. Using in vitro systems and an immunocompetent DLBCL mouse model, the project will define how metabolic targeting can strengthen anti-lymphoma immunity and guide future combination therapies.